XNCR - Xencor inks agreement with Janssen for the potential prostate cancer treatment

Xencor (XNCR) has entered into a research collaboration and license agreement with Janssen Biotech to focus on the discovery of XmAb bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed prostate tumor target, for the potential treatment of patients with prostate cancer.The company receives $50M upfront payment and is eligible to receive potential milestone payments and a royalty on net sales from commercialized medicinesUnder the terms of the agreement, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against the tumor target specified by Janssen.Preclinical activities and all clinical development, regulatory and commercial activities will be conducted by Janssen, which has exclusive worldwide rights to develop and commercialize the novel drug candidates.Source: Press Release

For further details see:

Xencor inks agreement with Janssen for the potential prostate cancer treatment